Year All20242023202220212020201920182017201620152014 Aug 19, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 15, 2024 Soleno Therapeutics Announces Updates to its Board of Directors Aug 07, 2024 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Jun 28, 2024 Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome Jun 24, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 04, 2024 Soleno Therapeutics Set to Join Russell 3000® Index May 22, 2024 Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 May 22, 2024 Soleno Therapeutics to Participate in Upcoming Investor Conferences May 15, 2024 Soleno Therapeutics Stands with the Prader-Willi Syndrome Community May 09, 2024 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Aug 07, 2024 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Jun 28, 2024 Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
May 22, 2024 Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
May 09, 2024 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results